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Comparison of immunogenicity 
and vaccine efficacy between heat-
shock proteins, HSP70 and GrpE, in 
the DnaK operon of Mycobacterium 
tuberculosis
Woo Sik Kim1,2, Jong-Seok Kim1,4, Hong Min Kim1, Kee Woong Kwon1, Seok-Yong Eum3 & 
Sung Jae Shin1
Antigens (Ags) in Mycobacterium tuberculosis (Mtb) that are constitutively expressed, overexpressed 
during growth, essential for survival, and highly conserved may be good vaccine targets if they induce 
the appropriate anti-Mtb Th1 immune response. In this context, stress response-related antigens of 
Mtb might serve as attractive targets for vaccine development as they are rapidly expressed and are 
up-regulated during Mtb infection in vivo. Our group recently demonstrated that GrpE, encoded by 
rv0351 as a cofactor of heat-shock protein 70 (HSP70) in the DnaK operon, is a novel immune activator 
that interacts with DCs to generate Th1-biased memory T cells in an antigen-specific manner. In this 
study, GrpE was evaluated as a subunit vaccine in comparison with the well-known HSP70 against the 
hyper-virulent Mtb Beijing K-strain. Both HSP70- and GrpE-specific effector/memory T cells expanded 
to a similar extent as those stimulated with ESAT-6 in the lung and spleen of Mtb-infected mice, but 
GrpE only produced a similar level of IFN-γ to that produced by ESAT-6 stimulation during the late 
phase and the early phase of Mtb K infection, indicating that GrpE is highly-well recognised by the host 
immune system as a T cell antigen. Mice immunised with the GrpE subunit vaccine displayed enhanced 
antigen-specific IFN-γ and serum IgG2c responses along with antigen-specific effector/memory T 
cell expansion in the lungs. In addition, GrpE-immunisation markedly induced multifunctional Th1-
type CD4+ T cells co-expressing IFN-γ, TNF-α, and IL-2 in the lungs of Mtb K-infected mice, whereas 
HSP70-immunisation induced mixed Th1/Th2 immune responses. GrpE-immunisation conferred a 
more significant protective effect than that of HSP70-immunisation in terms of bacterial reduction and 
improved inflammation, accompanied by the remarkable persistence of GrpE-specific multifunctional 
CD4+ T cells. These results suggest that GrpE is an excellent vaccine antigen component for the 
development of a multi-antigenic Mtb subunit vaccine by generating Th1-biased memory T cells with 
multifunctional capacity, and confers durable protection against the highly virulent Mtb K.
Although the prevention of tuberculosis (TB) is the most effective control measure to reduce the incidence of TB, 
the protection efficacy of bacillus Calmette-Guerin (BCG), the only currently available licensed TB vaccine1, is 
thought to be insufficient to protect against pulmonary TB and latent infection. In addition, variable results of 
BCG vaccine efficacy for different geographical locations have been reported because Mycobacterium tuberculosis 
(Mtb) genotypes with different virulence levels may be dominant in different regions2–4. Importantly, the Mtb 
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Beijing genotype is highly prevalent in East Asian countries including China, Korea, and Japan and the isolation 
rate of strains belonging to the Mtb Beijing family has increased worldwide, indicating that BCG vaccine pro-
vides a relatively low level of protection against this Mtb genotype5,6. Furthermore, epidemiological studies have 
recently suggested that continuous BCG vaccination may have driven the emergence of the Beijing genotype6. 
Thus, the control of Mtb Beijing strains is a major challenge and is urgently needed globally.
To develop new prophylactic vaccines capable of replacing and/or boosting the BCG vaccine, many vac-
cine candidates have entered into the clinical7,8. In particular, prophylactic vaccines require Ag targets that are 
expressed during the early phase of infection and are recognised by the host immune system to immediately 
initiate host defense mechanisms9,10.
It is well documented that host defense against Mtb infection is strongly associated with the expansion and 
generation of Mtb-specific multifunctional Th1-type T cell subsets, in concert, to activate macrophages, thereby 
limiting mycobacterial replication during the early infection period11,12. Thus, the identification of Ags triggering 
protective T cell subsets at the early infection course is a goal of TB vaccine development. In this regard, Ags in 
Mtb that are constitutively expressed, overexpressed during growth, essential for survival and growth, and highly 
conserved may be good vaccine targets if they induce a prompt anti-Mtb Th1 immune response13,14. Following 
this rationale, many Mtb vaccine Ag targets, including Ag85 complex antigens, ESAT-6 (early secreted anti-genic 
target-6), and heat shock proteins (HSPs), have been evaluated as target vaccine antigens because they are abun-
dantly expressed and induce a strong cell-mediated immune defense response by evoking T-cell proliferation and 
IFN-γ production in an antigen-specific dependent manner, especially during the early phase of Mtb infection15,16.
Accordingly, stress response-related antigens of Mtb are attractive targets for vaccine development, as they 
are rapidly expressed and up-regulated during Mtb infection17,18. HSPs are essential molecular chaperones for 
the maintenance of cellular functions in normal as well as stress conditions19. The regulation of the expression 
of HSPs plays an important role in the pathogenesis of Mtb20. Among mycobacterial HSPs, Mtb HSP70 is the 
most well-known Ag linking innate and adaptive immune responses with potent adjuvant activity21. In Mtb, the 
hsp70 operon consists of the dnaK-grpE-dnaJ (rv0350-rv0351-rv0352) genes and is co-expressed and negatively 
regulated by the repressor hspR (rv0353)22. The Dnak operon in mycobacterial species is essentially required for 
cell growth, even in the absence of stress, indicating that it is a promising target for the development of antibi-
otics and vaccines against mycobacteria23. Notably, due to the host immune response to HSPs, the constitutive 
over-expression of Mtb HSP70 results in the reduced survival of Mtb during prolonged infection24, indicating that 
it may be possible to design interventions capable of promoting an immediate and durable host immune response 
to control Mtb.
Although the role of HSP70 in the immune response to Mtb infection has been studied extensively, relatively 
little is known about its cofactor, GrpE, especially with respect to its immunological functions and TB vaccine 
potential. In addition, HSP70 and GrpE were recently identified as potential vaccine candidates in an in silico 
analysis of open reading frames in the Mtb genome25. Importantly, our group recently showed that Th1-type 
T-cell immunity-biasing effect of GrpE by intercommunicating with dendritic cells26.
In the present study, the immunogenicity and the potential protective efficacy of stress antigens in HSP70 and 
its co-factor GrpE in the DnaK operon were assessed in a head-to-head format in a Mtb Beijing strain challenge 
model by delivery as subunit vaccines. We found that GrpE is rapidly recognised by the host immune system and 
produces a similar level of IFN-γ to that produced by ESAT-6-stimulation during Mtb K infection. Following the 
challenge with Mtb K, the GrpE-subunit vaccine showed an equivalent protective efficacy to BCG immunisation 
against Mtb K by rapidly recruiting and activating GrpE-specific multi-functional CD4+ T cells in the lungs pre- 
and post-challenge, along with the expansion of antigen-specific Th1 and effector/memory T cells in the lungs of 
Mtb-infected mice. Thus, our results suggest that GrpE is a possible component of future multi-antigenic vaccines 
and therefore is a candidate for a novel TB vaccine.
Results
Purification of recombinant proteins. For the purification of recombinant proteins, HSP70 and GrpE 
were expressed with a 6× histidine-tag in E. coli BL21 (Fig. 1a). Both recombinant proteins were purified as sol-
uble forms; SDS-PAGE revealed that the molecular weights of HSP70 and GrpE were around 70 kDa and 32 kDa, 
respectively. The purified protein showed the expected molecular mass based on SDS-PAGE. Protein purification 
was ultimately confirmed by Western blotting. The endotoxin contents were measured by an LAL assay and were 
undetectable by showing below 10 pg/mL (<0.1 EU/mL) in both antigen preparations. These results indicate that 
HSP70 and GrpE were successfully purified for subsequent experiments.
HSP70 and GrpE induced an antigen-specific IFN-γ response and effector/memory T cell expansion 
in Mtb K-infected mice upon ex vivo re-stimulation. Many intracellular bacterial infections induce 
memory T cell and antigen-specific T cell responses by bacterial antigens27. Prior to evaluating the efficacy of 
the two vaccine antigen candidates, we investigated whether HSP70 and GrpE recognition by the host immune 
system can induce an immunological T cell activation along with memory response during the course of Mtb 
infection9. We therefore analysed the antigen-specific IFN-γ response (Fig. 1b) and the generation of effector or 
effector/memory CD4 T cells (Fig. 1c) by HSP70, GrpE, or ESAT-6 (as a positive control) stimulation in T cells 
of Mtb-infected mice. Single cell suspensions from the lung and spleen of Mtb K-infected mice were prepared 
at 4 and 8 weeks post-infection. The cells were stimulated with HSP70 and GrpE for 24 h, and IFN-γ produc-
tion was analysed by ELISA (Fig. 1b). As shown in Fig. 1b, lung and spleen cells from the Mtb K-infected mice 
show higher levels of IFN-γ in response to GrpE stimulation compared to those for HSP70 stimulation. Also, we 
measured effector (CD44+CD127+CD62L− cells) and effector/memory (CD44+CD127+CD62L+ cells) via the 
surface expression of CD44 and CD127 on CD3+CD4+-gated CD62L− by flow cytometry (Fig. 1c; top panel). 
Both HSP70 and GrpE stimulation substantially increased effector/memory T cells, but there was no difference 
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between HSP70 and GrpE stimulation (Fig. 1c; bottom panel). Taken together, HSP70 and GrpE are immunolog-
ically recognised during Mtb K infection; thus, Ag-specific memory T cells are generated.
Immunogenicity and immunological memory induced by HSP70 and GrpE immunisation. 
Incomplete Freund’s adjuvant (IFA), which lacks mycobacterial components, was used in this study. We first 
investigated the IFN-γ response of T cells after BCG and IFA-based antigen immunisation. After the final immu-
nisation, we assessed IFN-γ responses (Fig. 2b,c), as well as the up-regulation of antigen-specific IFN-γ-producing 
memory Th1 cells (Fig. 2d,e) upon cognate antigen stimulation in the spleen and lung cells of immunised 
mice. Purified protein derivative (PPD) was used as a stimulant for the T cells of the BCG vaccine-immunised 
mice. Antigen-specific IFN-γ+ T cells were evaluated by T cell specific markers (CD3+CD4+ and CD3+CD8+) 
and activated or a memory Th1 cell marker (CD44high) using flow cytometry (Fig. 2d). BCG-, HSP70- and 
GrpE-immunisation induced IFN-γ release (Fig. 2b,c) and the number of IFN-γ+CD44highCD4+ and CD8+ T 
cells (Fig. 2e) in response to re-stimulation with PPD, HSP70, and GrpE were measured. A further analysis of 
the antigen-specific IgG1 response, an indicator of the Th2 response, showed that the HSP70-immunised groups 
exhibited a HSP70-specific IgG1 response. Additionally, all groups exhibited an elevated IgG2c response, an indi-
cator of the Th1 response, compared with that of adjuvant control groups (Fig. 2f).
Figure 1. IFN-γ production and memory T cell phenotypes induced by recombinant antigen stimulation 
in the lung and spleen of Mtb K-infected mice. (a) HSP70 and GrpE antigens were successfully induced in 
E. coli BL21 by supplementation with 1 mM isopropyl β-d-thiogalactoside (IPTG) for 12 h. (a, 1 and 4) The 
expression of N-terminal His-tagged antigens was identified by SDS-PAGE (M, molecular weight markers; 
Lane 1, uninduced; Lane 2, induced). (a, 2 and 5) SDS–PAGE analysis of purified antigens by Ni-nitrilotriacetic 
acid (NTA). (a, 3 and 6) Western blot analysis of purified antigens using mouse anti-His antibodies. (b) HSP70 
(10 μg/mL)- and GrpE (10 μg/mL)-specific IFN-γ production were measured in the spleen and lung cells of 
individual mice 4 and 8 weeks after challenge with aerosolised Mtb K strain (n = 4 mice/group). NI: Non-
infected mice, K: Mtb K-infected mice. ESAT-6 (1 μg/mL) was used as a positive control. Data from one of two 
independent experiments are shown. (c) At the same time point, spleen and lung cells from Mtb K-infected 
mice (n = 4 mice) were stimulated in vitro with antigens, and numbers of CD4+ effector/memory and effector 
T cells were analysed by flow cytometry. Data from one of two independent experiments are shown. All results 
are expressed as means ± SD and statistical significance (*p < 0.05, **p < 0.01, or ***p < 0.001) is shown for 
treatments compared to the non-treated each T cells (non; effector or effector/memory T cells, respectively). 
The value of n.s. was defined as no significant effect.
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Protective efficacy of the antigen vaccine in the Mtb K-infected mouse model. Four weeks after 
the last immunisation, the ability of protein vaccines to protect against Mtb K was analysed by aerosol challenges. 
For the histopathological analysis, lungs were isolated and stained with H&E at 4 and 8 weeks post-infection. The 
lungs of adjuvant alone-, HSP70-, GrpE-, and BCG vaccine-immunised groups (as a positive control for the effi-
cacy testing of TB vaccines in this study) were analysed with respect to histology (Fig. 3a,b) and bacterial burden 
(Fig. 3c). Lung tissues from GrpE- and BCG vaccine-immunised mice 4 and 8 weeks after Mtb K challenge clearly 
showed reduced granulomatous inflammation compared to the lung tissues of the adjuvant control group, along 
with the microscopic appearance (Fig. 3b). However, a reduction of granulomatous inflammation via HSP70 
immunisation was only observed at 4 weeks post-infection. In addition, with respect to bacterial burden, the 
group immunised with GrpE showed a significant reduction of CFUs in the lung and spleen at 4 and 8 weeks after 
Figure 2. Immunogenicity in the lung and spleen of HSP70- and GrpE-immunised mice. (a) Schematic 
diagram of the subunit vaccine experimental design. (b,c) Mice (n = 5 mice/group) were immunised with BCG 
(Red bars), HSP70 (Black bars), GrpE (Blue bars), or adjuvant alone (Green bars), and their spleen and lung 
cells were stimulated in vitro with no antigen, PPD, HSP70, or GrpE 4 weeks after the last vaccination. IFN-γ 
secretion by spleen and lung cells in response to PPD (b,c), HSP70 (b) and GrpE (c) stimulation was analysed 
by ELISA. (d) An example of the gating strategy for the analysis of antigen-specific IFN-γ producing T cells 
among lung T cells of one representative mouse from the GrpE-immunised group is shown. (e) The percentages 
of PPD-, HSP70- or GrpE-specific IFN-γ-producing CD3+CD4+CD44high and CD3+CD8+CD44high T cells were 
analysed in cells isolated from the spleen and lungs of BCG- and antigen-immunised mice (n = 5 mice/group). 
(f) Serum levels of antigen-specific IgG1 and IgG2c at 4 weeks after the final immunisation (n = 5 mice/group). 
Data from one of two independent experiments are shown. *p < 0.05, **p < 0.01, or ***p < 0.001, compared to 
the adjuvant control group (Green bars).
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Mtb K challenge compared to the adjuvant alone group. HSP70 immunisation had a minor effect on the bacte-
rial burden in lung and spleen (Fig. 3c). However, 8 weeks post the Mtb K challenge, the degree of pathological 
improvement observed after GrpE vaccination was lesser than that observed after BCG immunisation (Fig. 3b).
GrpE immunisation dominantly increases the Th1 immune response during the course of Mtb K 
infection, while HSP70 immunisation simultaneously induces mixed Th1/Th2 responses. Because 
a decrease in multifunctional T cells is associated with increased bacterial growth in active Mtb-infection mod-
els28, both the Th1-type immune response and multifunctional T cells may be potential correlates of an effective 
host-protective immune response in TB29. Base on established the methodology from the previous study for multi-
ufnctionality of T cells30, we next assessed the T cell phenotype and immune responses that are induced following 
antigen vaccination. At 4 and 8 weeks after the challenge, lung cells (top panel of Figs 4a and 5a) and splenocytes 
(bottom panel of Figs 4a and 5a) were stimulated in vitro with PPD, HSP70 or GrpE and the phenotypes of CD4+ 
(Fig. 4) and CD8+ (Fig. 5) antigen-specific T cells were evaluated by multi-colour intracellular cytokine staining 
and flow cytometry (Supplementary Fig. S1). Culture supernatants containing the secreted cytokines were collected 
from splenocytes and lung cells after antigen re-stimulation and analysed by ELISA (Fig. 6). As a consequence, 
the groups immunised with BCG, HSP70, or GrpE exhibited robust responses against their respective antigens 
after re-stimulation. Interestingly, increased levels of triple-positive (IFN-γ+TNF-α+IL-2+) and double-positive 
(IFN-γ+TNF-α+) antigen-specific CD4+CD44high T cells were observed in the BCG-, GrpE-immunised group 
compared to the control groups in the spleen and lung at 4 and 8 weeks post-infection (Fig. 4), and triple-positive 
(IFN-γ+TNF-α+IL-2+) and double-positive (IFN-γ+TNF-α+ and TNF-α+IL-2+) antigen-specific CD8+CD44high 
T cells were observed in the lung at 4 weeks post-infection. In the BCG-immunised groups, the cells were 
Figure 3. Protective efficacy of antigen immunisation against Mtb K infection. (a) H&E-stained sections 
(n = 5 mice/group) of the lung for each immunised mouse (Adjuvant alone, BCG, HSP70, or GrpE) at 4 and 8 
weeks after challenge with the aerosolised Mtb K strain. One BCG vaccinated group was included as a positive 
control. (b) Lung inflammation values are presented as the mean percentages of the area of inflammation from 
lung sections of infected mouse groups. (c) The differences in bacterial numbers between vaccinated groups 
and adjuvant control groups at 4 and 8 weeks after challenge are shown. Data from one of two independent 
experiments are shown. *p < 0.05, **p < 0.01, or ***p < 0.001, when compared to adjuvant control group; 
green bars or plots (a one-way ANOVA followed by Dunnett’s test). #p < 0.05 (BCG vs. GrpE; unpaired t-test).
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well-maintained for up to 8 weeks post infection (Fig. 5). However, in the case of the HSP70-immunised group, 
cytokine-secreting CD4+ and CD8+ T cells were significantly decreased in the lung and spleen compared with 
those of the BCG- or GrpE-immunised group (Figs 4 and 5). Furthermore, the lung and spleen of mice immunised 
with HSP70 induced Th1-related cytokines together with Th2-related cytokines, such as IL-5 and IL-10 (Fig. 6a), 
whereas BCG and GrpE-immunisation induced a significantly higher frequency of Th1-related cytokines, including 
TNF-α, IFN-γ, and IL-2 (Fig. 6b). Interestingly, antigen-specific IgG1 and IgG2c responses did not differ signifi-
cantly between adjuvant control groups and antigen-immunised groups after Mtb infection (data not shown). These 
findings suggest that GrpE immunisation induces a greater Th1 response than HSP70 immunisation, but not a 
humoral response.
Discussion
Inside host cells such as macrophages and dendritic cells, Mtb may experience many harsh conditions. In particu-
lar, Mtb Ags play important roles in cell-to-cell communication, detoxification, eliciting host immune responses, 
and essentially aiding in Mtb growth. They are of great interest as vaccine antigen targets because their expression 
is obligatory for Mtb survival and they are likely to be recognised by host immune cells.
Figure 4. Antigen-specific multifunctional CD4+ T cell responses in antigen-immunised mice after challenge 
with Mtb K. BCG-, HSP70-, GrpE-, or adjuvant alone-immunised mice were infected by aerosol exposure 
to Mtb K. At different time points after infection, as indicated, mice (n = 5 mice/group at 4 and 8 weeks 
post-infection) were euthanised and their lung cells (a and b; top panel) and splenocytes (b; bottom panel) 
were stimulated in vitro with PPD (10 μg/mL), HSP70 (10 μg/mL) or GrpE (10 μg/mL). (a) The percentage of 
antigen-specific CD4+CD44high T cells producing IFN-γ, TNF-α, or IL-2 was measured by use of the gating 
strategy shown in Supplementary Fig. S1, in cells isolated from lung cells and splenocytes at 4 and 8 weeks after 
challenge with Mtb K strain. (b) The pie charts present the mean frequencies of cells co-expressing IFN-γ, TNF-
α, and/or IL-2. The cytokine profiles for individual cells were analysed by multi-colour flow cytometry by gating 
for lymphocytes, CD3+CD4+CD44high. Data from one of two independent experiments are shown. *p < 0.05, 
**p < 0.01, or ***p < 0.001 relative to the control groups, respectively.
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Overall, effective Ag targets for the rational design of Mtb vaccines should satisfy the following requirements: 
constitutive expression, accessibility (cell wall-associated or secreted) to Ag-presenting cells (APCs), recognised 
by the immune system during the early infection phase in vivo, ability to induce a Th1-biased memory immune 
response, and eventual efficacy against hyper-virulent Mtb strains. In this study, we evaluated antigens in the 
DnaK operon as vaccine candidates that fulfil these criteria and are effective against challenge with the highly 
virulent Mtb K strain in a head-to-head comparison format.
In vaccine design, early protection by the rapid recruitment of IFN-γ-producing CD4+ effector T cells to 
the infected site is crucial because once acquired immunity is initiated, Mtb growth is inhibited31. For example, 
ESAT-6 is recognised promptly by T cells with strong immunogenicity at the early phase of infection and is a 
major antigen component of many prophylactic vaccine candidates16,32. However, it is believed that ESAT-6 is 
a key factor in diagnostic tools33,34, indicating that ESAT-6-based vaccines may be difficult for differentiation 
between naturally infected subjects and vaccinated people. Thus, a novel T cell antigen recognised by the host 
immune system at the early phase of infection is required for TB vaccine development, without interfering with 
diagnosis. In the present study, we first investigated whether HSP70 and GrpE are recognised by the host immune 
system during the early (4 weeks) and late (8 weeks) phases of Mtb infection by comparisons with ESAT-6. In our 
study, IFN-γ production (Fig. 1b) and CD4+ memory T cell expansion (Fig. 1c) were observed in spleen and lung 
cells isolated from mice treated with HSP70 and GrpE at various time points after infection with Mtb K, indicat-
ing that both antigens are recognised by the host immune system as immunogenic antigens. In particular, GrpE 
Figure 5. Antigen-specific multifunctional CD8+ T cell responses in antigen-immunised mice after Mtb K 
challenge. (a) The percentage of antigen-specific CD8+CD44high T cells producing IFN-γ, TNF-α, or IL-2 
measured in cells isolated from the lung (a and b; top panel) and splenocytes (a and b; bottom panel) of 
vaccinated mice (n = 5 mice/group at 4 and 8 weeks post-infection) at 4 and 8 weeks after challenge with 
Mtb K. The pie charts present the mean frequencies of cells co-expressing IFN-γ, TNF-α, and/or IL-2. The 
cytokine profiles for individual cells were analysed by multi-colour flow cytometry by gating for lymphocytes, 
CD3+CD8+CD44high. Data from one of two independent experiments are shown. *p < 0.05, **p < 0.01, or 
***p < 0.001 relative to the control groups, respectively.
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exhibited a comparable IFN-γ response to that of ESAT-6, the most well-characterised immunogenic Mtb Ag at 
the active phase of Mtb infection35, suggesting that GrpE is promptly recognised by the host immune system.
In fact, grpE is an essential gene, as determined by Himar1-based transposon mutagenesis, in the H37Rv 
strain and is highly conserved in all Mtb strains, with only a single gene copy36–38. In addition to the constitutive 
overexpression of grpE, basal grpE expression is essentially required for the survival and growth of Mtb, indicating 
that the obligatory expression of GrpE occurs during Mtb infection. Moreover, the over-expression of GrpE was 
identified in the most prevalent clinical Mtb strains from South India under hypoxic culture conditions compared 
to aerated cultures, while other HSPs, including HSPX, GroEL2, and GroES, are more highly expressed than the 
expression in the laboratory-adapted strain H37Rv, indicating that GrpE is up-regulated during clinical Mtb 
infection and may have vaccine potential39.
In general, high CD44 expression on T cell surfaces indicates that the T cells are antigen-experienced (i.e., 
they exhibit an antigen-specific memory phenotype)30,40. In addition, a recent study has shown that CD44 is 
essential for the generation and maintenance of memory T helper 1 (Th1) cells41. Interestingly, HSP70- and 
GrpE-immunised mice showed increased populations of IFN-γ+CD44high T cells in both the lung and spleen 
(Fig. 2e). Notably, both serum IgG1 and IgG2c, which are representative antibody isotypes for Th2 and Th1 
responses42, respectively, increased in HSP70-immunised mice, but only the IgG2c antibody response increased 
significantly in GrpE-immunised mice (Fig. 2f). The C-terminal portion of the heat shock protein Hsp70 has an 
adjuvant function by stimulating Th1-polarizing cytokines in human monocytes to produce IL-12, TNF-α, NO, 
and C-C chemokines43. Furthermore, Mtb HSP70 induces the expression of IL-10 and inhibits T-cell proliferation 
in vitro, indicating that HSP70 has immunomodulatory properties, rather than inflammatory potential44.
Based on these results, we evaluated and compared the protective effects of HSP70 and GrpE subunit vac-
cines against the Mtb K strain in a mouse model. Interestingly, GrpE immunisation displayed a protective effect 
comparable to that of the BCG vaccine in terms of CFU reduction, while HSP70 showed marginal protection, 
indicating that GrpE showed better protection than HSP70 after challenge with the Mtb K strain based on assess-
ments of lung pathology (Fig. 3a,b) and the reduction of bacterial CFUs (Fig. 3c). However, the mice in the BCG 
Figure 6. T cell immunity induced by antigen immunization. (a,b) Spleen and lung cells from BCG-, adjuvant 
alone-, HSP70-, and GrpE-immunised mice (n = 5 mice/group at 4 and 8 weeks post-infection in each group) 
were stimulated with PPD, HSP70, or GrpE, and the supernatant was collected and assayed for cytokines by 
ELISA. Antigen-specific cytokine responses are shown for spleen and lung cells collected post-infection (4 and 
8 weeks). Data from one of two independent experiments are shown. *p < 0.05, **p < 0.01, or ***p < 0.001 by 
unpaired t-tests.
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vaccination group showed a more substantial CFU reduction (spleen, 8 weeks post infection, p < 0.05) and atten-
uated lung inflammation, compared to the single GrpE-immunised mice (Fig. 3; lungs, 8 weeks post infection, 
p < 0.05). These results suggest that the live BCG vaccine contains many Ags that may augment the functions of a 
variety of agents of the protective T cell repertoire, including the antigen 85 complex45,46.
Recently, Forbes et al. showed that multifunctional abilities of T cells are associated with protection against 
Mtb infection in a mouse model47. In addition, a continuous decrease in the multifunctionality of T cells cor-
responds with a decrease in protection against challenge with Mtb in the mouse model29. Thus, we used 
multi-parameter flow cytometry to analyse CD4+ and CD8+ T cells at infectious site after immunisation. In 
this study, the GrpE immunisation remarkably induced a high frequency of multifunctional CD4+CD44high T 
cells (IFN-γ+TNF-α+IL-2+, IFN-γ+TNF-α+, and TNF-α+IL-2+) in the spleen and lung, while less induction was 
observed in the HSP70-immunised group (Figs 4 and 5). In addition, in GrpE-immunised mice, significantly 
higher levels of Th1-related cytokines were induced, including TNF-α, IFN-γ, and IL-2, while HSP70-immunised 
mice exhibited the induction of Th1-related cytokines along with Th2-related cytokines, such as IL-5 and IL-10 
(Fig. 6). In general, the Th2 type immune response is reported to be harmful for immunity against Mtb infection. 
Aron et al. reported that the adoptive transfer of Th2 cells leads to an increase in CFUs of Mtb in the lung48. In 
addition, mixed Th1/Th2 immune responses occur in patients with active tuberculosis49. Thus, the mixed Th1/
Th2 immune response and IgG1/IgG2c antibody responses and immune responses may be responsible for a rel-
atively lower level of protection in the HSP70-immunised group; the robust Th1 immune response induced by 
GrpE immunisation was associated with a high level of protection against Mtb K infection.
Taken together, GrpE is recognised by the immune system at the early phase of infection and has the ability to 
induce a robust and durable Ag-specific multifunctional Th1-type T-cell memory response, conferring protective 
immunity and imparting significant protection in a murine model against the Mtb K strain. These results indicate 
that GrpE is a potential Ag target for the development of future multi-antigenic vaccines against Mtb, especially 
against highly virulent Mtb Beijing strains. Furthermore, the efficacy of a BCG priming vaccination combined 
with a GrpE subunit vaccine should be investigated to determine whether the GrpE subunit vaccine can boost the 
efficacy of the BCG vaccine.
Methods
Ethics statement and animals. All animal experiments were conducted following the guidelines pro-
vided by the Korean Food and Drug Administration (KFDA). The experimental procedures were evaluated and 
approved by the Institutional Animal Care and Use Committee (Permit Number: 2015-0041) of Yonsei University 
Health System (Seoul, Korea). After obtaining permission for the experiments, specific pathogen-free (SPF) 
female C57BL/6J mice at 6–7 weeks of age were purchased from Japan SLC, Inc. (Shizuoka, Japan) and main-
tained under barrier conditions in a ABSL-3 facility at the Avison Biomedical Research Center in Yonsei College 
of Medicine. The animals were fed a sterile commercial mouse diet and provided water ad libitum.
Expression and purification of recombinant proteins. Cloning was conducted in Escherichia coli  
(E. coli) DH5α. rv0350 and rv0351 were amplified from Mtb H37Rv (ATCC 27294) genomic DNA by polymerase 
chain reaction (PCR). The rv0350 primers were as follows: 5′-GGGCCCCATATGGCTCGTGCGGTCGGGATC-3′ 
(forward primer; the NdeI site is underlined) and 5′-GGGCCCAAGCTTCTTGGCCTCCCGGCCGTCGTC-3′ 
(reverse primer; the HindIII site is underlined). The rv0351 primers were as follows: 5′-CGCCATATGGTGACGGACG 
GAAATCAAAAGC-3′ (forward primer; the NdeI site is underlined) and 5′-CCCAAGCTTACTGCCCGAC 
GGTTCTGATTC-3′ (reverse primer; the HindIII site is underlined). The amplified PCR products were inserted 
into the pGEMT Easy Vector and sequences of the plasmids with rv0350 and rv0351 insertions were analysed. 
Finally, these genes were ligated into pET22b (Novagen, Madison, WI, USA) and transferred to E. coli BL21 cells.
Expression and purification of proteins. The expression and purification of recombinant proteins 
were performed as described previously50. For protein expression, transformed E. coli (pET22b-rv0350 and 
pET22b-rv0351) and vector controls (pET22b in E. coli BL21 cells) were incubated in LB broth supplemented 
with 50 μg/mL ampicillin and 1 mM isopropyl-β-d-thio-galactoside (IPTG) at 37 °C for 12 h. To confirm the 
protein expression and purification, each step was evaluated by 12% SDS-PAGE with Coomassie brilliant blue 
staining and immunoblotting using an anti-His antibody (Lab Vision, Fremont, CA, USA). To remove endotoxin 
contamination, the dialyzed proteins were incubated with polymyxin B-agarose (Sigma, St. Louis, MO, USA) and 
analysed using the limulus amebocyte lysate (LAL) test (Lonza, Lockland, ME, USA), according to the manufac-
turer’s instructions. The purity of antigens was quantified using Quantity One (Bio-Rad, Hercules, CA, USA); 
values were obtained by dividing the intensity per square millimeter of the HSP70- and GrpE-specific bands by 
that of all protein bands in the preparation lane.
Bacteria and culture condition. Mtb H37Rv (ATCC 27294) was purchased from the American Type 
Culture Collection (ATCC, Manassas, VA, USA), and the Mtb K strain was obtained from the strain collections at 
the Korean Institute of Tuberculosis (KIT, Osong, Chungchungbuk-do, Korea). BCG (Pasteur 1173P2) was kindly 
provided by the Pasteur Institute (Paris, France). The mycobacterial strains used in this study were cultured as 
described previously51. Enumerated mycobacteria were used for subsequent experiments.
Analysis of memory responses induced by antigen stimulation in T cells during the course of Mtb 
infection. C57BL/6 mice were aerogenically infected with Mtb K as previously described52. The bacteria were 
counted 1 day after aerosol exposure; approximately 150 viable bacteria were found to be delivered to the lungs. 
4 and 8 weeks post infection, single-cell suspensions from the spleen and lungs of Mtb K-infected mice were 
prepared as described previously14. The single-cell suspensions were stimulated with antigens (HSP70, GrpE, and 
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ESAT-6) for 24 h at 37 °C, and then, the cells and culture supernatants were examined for IFN-γ production and 
effector/memory T cell responses using ELISA assay and flow cytometric analysis, respectively.
Immunisation and evaluation of vaccine efficacy in a murine model. For the adjuvant control and 
antigen vaccination groups, C57BL/6 J mice were immunised subcutaneously 3 times at 3-week intervals with 
incomplete Freund’s adjuvant (Sigma) (Adjuvant; 20 μg), HSP70 (antigen; 10 μg, Adjuvant; 20 μg), and GrpE 
(antigen; 10 μg, Adjuvant; 20 μg). Groups vaccinated with BCG (as positive control for the efficacy testing experi-
ment of TB vaccine) were subcutaneously vaccinated with 3 × 105 CFU of BCG Pasteur 1173 P2 at the time of the 
2nd immunisation using the antigens. Four weeks after the last immunisation, 5 mice per group were euthanized 
to analyse the immune responses, and adjuvant controls and vaccinated mice were aerogenically infected with 
Mtb K as previously described52. Briefly, mice were exposed to Mtb K for 60 min in the inhalation chamber of 
an airborne infection apparatus calibrated to deliver a predetermined dose (Glas-Col, Terre Haute, IN, USA). 
To confirm the initial bacterial burden, four mice were euthanised one day later, and approximately 150 viable 
bacteria were delivered to the lungs of each mouse. This in vivo protective efficacy test was conducted twice. At 
4 and 8 weeks after the Mtb K challenge, single-cell suspensions from the spleen and lungs of BCG-, HSP70-, 
and GrpE-immunised mice were stimulated with antigens (PPD, HSP70, and GrpE; 10 μg/mL concentrations) 
for 12 h at 37 °C in the presence of GolgiStop (BD Biosciences, San Diego, CA, USA), and then, the popula-
tions of antigen-specific CD44high T cells producing IFN-γ, TNF-α, and/or IL-2 were analysed by flow cytometry. 
Additionally, the cytokines released into in the culture supernatants 24 h after antigen stimulation at 37 °C in the 
absence of GolgiStop were quantified using ELISA.
ELISA for serum IgG titres. Antigen-specific IgG1 (Sigma) and IgG2c (Southern Biotech, Birmingham, 
AL, USA) responses in serum from antigen-immunised mice were analysed by sandwich ELISA, as described 
previously14. Briefly, antigen-specific Abs were detected on 96-well plates coated with 1 μg/mL antigens, and 
blocked with PBST supplemented with 5% BSA. Serum samples diluted from 1/1000 were incubated for 24 h at 
4 °C. To detect antigen-specific IgG1 and IgG2C, incubation with HRP-conjugated Abs was performed for 1 h at 
37 °C. Optical densities (OD) were determined at 495 nm within 15 min of stopping the reaction.
Colony forming units (CFU) and histopathology. At 4 and 8 weeks after the Mtb K challenge, the num-
bers of viable bacteria in the lung and spleen were obtained for CFU counts. Briefly, each bacterial count was 
determined by plating serial dilutions of the organ homogenates onto Middlebrook 7H10 agar (Becton Dickinson, 
Franklin Lakes, NJ, USA) supplemented with 10% OADC enrichment medium until the late-exponential phase. 
The numbers of colonies were counted after 3 weeks of incubation at 37 °C. The resultant values were reported 
as the mean log10CFU ± SD per gram of lung and spleen tissues. Lung samples collected for histopathology were 
preserved overnight in 10% normal buffered formalin, embedded with paraffin, cut into 4–5-mm sections, and 
stained with hematoxylin-eosin (H&E). A specialised pathologist evaluated the inflammation level in the tissue 
sections from the lung in a blinded manner.
Intracellular cytokine staining and analysis of T cell subpopulations. Single cell suspensions from 
the spleen and lung were prepared as described preciously14. Single-cell suspensions (2 × 106 cells) from adjuvant-, 
BCG- and antigen-immunised mice were stimulated with PPD (10 μg/mL), HSP70 (10 μg/mL), or GrpE (10 μg/mL) 
for 12 h at 37 °C in the presence of GolgiStop. Cells were first blocked with Fc Block (anti-CD16/32; eBiosci-
ence, San Diego, CA, USA) for 15 min at 4 °C and then stained with fluorochrome-conjugated Abs to Live/Dead 
(InvivoGen, San Diego, CA, USA), CD3 (BD Biosciences), CD4 (eBioscience), CD8 (eBioscience), CD62L (eBi-
oscience), CD44 (eBioscience), and CD127 (eBioscience) for 30 min at 4 °C. Cells stained with the appropriate 
isotype-matched immunoglobulin were used as negative controls. After they were washed with PBS twice, cells 
were fixed and using a Cytofix/Cytoperm Kit (BD Biosciences) according to the manufacturer’s instructions. 
Intracellular TNF-α (eBioscience), IL-2 (eBioscience), and IFN-γ (eBioscience) were detected with 
fluorescein-conjugated Abs in a permeation buffer. Cells were analysed using a FACSverse flow cytometer and 
commercially available software (FlowJo).
Cytokine measurements. The levels of cytokines, such as IL-17, IL-5, TNF-α, IL-10, IL-2, and IFN-γ, were 
measured by ELISA, according to the manufacturer’s instructions (eBioscience).
Statistical analysis. All analyses were repeated at least two times with consistent results. The levels of sig-
nificance for comparisons between samples were determined by Dunnett’s post-test or unpaired t-tests using 
statistical software (GraphPad Prism, version 5; San Diego, CA, USA). Results are expressed as means. Values of 
*p < 0.05, **p < 0.01, and ***p < 0.001 were considered statistically significant.
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